Fibrillarin upregulation correlates with poor prognosis in breast cancer and AML (Luo and Kharas, 2024; Marcel et al., 2013), whereas its downregulation is also linked to adverse outcomes in breast cancer (Nguyen Van Long et al., 2022). The gene discussed is FBL; the disease is breast cancer.